Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: dwight martin who wrote (1989)	2/10/2002 9:31:26 PM
From: The Fox	Respond to of 2515

Dwight... Was moving up through the stack and didn't see your post. I apologize for the duplicate post. The Fox

To: dwight martin who wrote (1989)	2/11/2002 9:22:22 AM
From: Fred Levine	Respond to of 2515

Dwight-- I agree with Cacaito that anecdotal and/or case reports, however encouraging, are insufficient for approval. What I don't agree with him is that the motives of the Waksuls were malevolent. Clinicians, patients, and researchers feel helpless while cancers spread and the prognoses motivates encourageing promising treatments. That is the gist of my argument. Erbotux is certainly promising. To repeat, I visualize reporters having saliva dribble while they write about the very open and beneficial to all shareholder tender offer. That writing indicates the slant in the press. fred